Trifecta Valve Gets Approval From European Union And… Joe
Wednesday, March 10th, 2010As many of you know, this is a very exciting time for the heart valve surgery community given the rapid advance of medical technologies used to treat diseases including aortic stenosis and mitral regurgitation.
Last week, St. Jude Medical, one of the leading heart valve manufacturers, cleared a significant hurdle for the commercial release of its new Trifecta heart valve replacement. In case you missed it, St. Jude announced that its Trifecta valve received CE mark approval for the device within the European Union. (The device is still in clinical trials here in the United States.)

Trifecta Heart Valve (Source: Medgadget)
As we have discussed before, the Trifecta heart valve is a pericardial, stented tissue valve used to replace a patient’s diseased, damaged or malfunctioning aortic heart valve. According to the St. Jude, this next-generation tissue valve has a tri-leaflet stented pericardial design which offers excellent hemodynamic performance, or nearly unobstructed blood flow, which closely mimics the blood flow of a natural, healthy heart. The valve also features the Linx AC Technology, an anti-calcification treatment designed to reduce tissue mineralization (hardening).







